CCR-3 receptor antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S357000, C514S428000, C514S528000, C514S613000, C544S333000, C548S567000, C558S432000, C564S189000, C546S336000

Reexamination Certificate

active

07049317

ABSTRACT:
The invention provides compounds of Formula (I):wherein R1–R4have any of the values defined in the specification that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use, and methods and intermediates useful for preparing them.

REFERENCES:
patent: 4098904 (1978-07-01), Szmuszkovicz
patent: 4204003 (1980-05-01), Szmuszkovicz
patent: 6166015 (2000-12-01), Rogers et al.
patent: 6462076 (2002-10-01), Gabriel et al.
patent: 6576792 (2003-06-01), Kim
patent: 6706712 (2004-03-01), Cherney
patent: 4326344 (1995-02-01), None
patent: 2729140 (1996-07-01), None
patent: WO 94/20062 (1994-09-01), None
patent: WO 99/64394 (1999-12-01), None
Kertesz, et al., “2,4-Substituted Pyrrolidine Derivatives—CCR-3 Receptor Antagonists”. Regular U.S. Appl. No. 10/034,034, filed Dec. 19, 2001 (priority claim: U.S. Appl. No. 60/256,585, filed Dec. 19, 2000).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

CCR-3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CCR-3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR-3 receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3614225

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.